# Orforglipron

> Orforglipron is an investigational oral, non-peptide GLP-1 receptor agonist studied for obesity and type 2 diabetes. Because it is a small molecule rather than a peptide, it does not require injection or the cold-chain handling many GLP-1 peptides need. Late-stage trials have reported average weight reductions comparable to some injectable GLP-1 agents, though it has not yet received regulatory approval. Ongoing studies continue to evaluate its long-term efficacy and safety.

- URL: https://www.lifeconverted.com/peptides/orforglipron
- Also known as: LY3502970
- Primary category: Weight Management
- Effectiveness rank: #17 in Weight Management
- Evidence level: Moderate evidence
- Route: Oral (Non-peptide small-molecule GLP-1 agonist taken as an oral tablet, distinguishing it from injectable peptide GLP-1 agonists.)
- Dose range: 3-36 mg
- Dose tiers: low 3 mg; moderate 12 mg; high 36 mg
- Half-life: Approximately 1-2 days, supporting once-daily oral dosing
- Timing: Morning, empty stomach
- Cycle: Continuous daily use with titration in trial protocols on, Not established outside of trial settings off
- Storage: Store tablets at room temperature, protected from moisture, per manufacturer labeling for oral formulations.

## Mechanism of action

Orforglipron binds to and activates the GLP-1 receptor despite being structurally unrelated to the native GLP-1 peptide. Receptor activation slows gastric emptying and reduces appetite signaling in the central nervous system, similarly to peptide GLP-1 agonists, but the oral small-molecule format avoids the manufacturing and administration complexity of injectable peptides.

## Reported benefits

- Oral administration avoids the need for injections
- Associated with meaningful average weight loss in late-stage trials
- May improve glycemic control
- No cold-chain storage requirement reported for the tablet formulation

## Reported side effects

- Nausea, vomiting, and diarrhea, especially during dose escalation
- Decreased appetite
- Potential gallbladder-related events
- Long-term safety data remain limited outside of trial settings

## Common protocols

- Trial-based daily oral titration schedule increasing dose over several weeks

## Stacking notes

Not established; combination with other GLP-1 agents is not supported by published research.

---

Educational information only, not medical advice. Full disclaimer: https://www.lifeconverted.com/disclaimer